38.99
前日終値:
$39.38
開ける:
$38.99
24時間の取引高:
5,597
Relative Volume:
0.21
時価総額:
$2.60B
収益:
$136.33M
当期純損益:
$-56.34M
株価収益率:
-51.96
EPS:
-0.7504
ネットキャッシュフロー:
$-18.87M
1週間 パフォーマンス:
-1.79%
1か月 パフォーマンス:
+59.80%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
AAPG を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
AAPG
Ascentage Pharma Group International Adr
|
38.99 | 2.60B | 136.33M | -56.34M | -18.87M | -0.7504 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-27 | 開始されました | JP Morgan | Overweight |
Ascentage Pharma Group International Adr (AAPG) 最新ニュース
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL - GlobeNewswire Inc.
Ascentage Pharma’s Studies to be Featured at 2025 EHA Congress - TipRanks
Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress - marketscreener.com
Ascentage Pharma Unveils Promising Data on Alrizomadlin at ASCO 2025 - TipRanks
Ascentage Pharma Announces Successful AGM Resolutions on May 19, 2025 - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA) - The Globe and Mail
Ascentage Pharma Files Annual Report, Announces Shareholder Meeting By Investing.com - Investing.com South Africa
Ascentage Pharma Files Annual Report, Announces Shareholder Meeting - Investing.com
JPMorgan sets Ascentage Pharma stock to Overweight, $27 target - Investing.com
Takeda Pharmaceutical Company (TKPYY) Stock: Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Ascentage Pharma to Announce 2024 Financial Results and Corporate Update - TipRanks
Avoid the Trap: 3 High-yield Dividend Stocks With Safe Payouts - The Globe and Mail
Ascentage Pharma IPO opens flat - Investing.com
Ascentage Pharma shares slide ahead of ADS debut on Nasdaq - Investing.com
Ascentage prices first biotech IPO of 2025, raising $126M - BioPharma Dive
Ascentage Pharma sets terms for $149 million US IPO - The Pharma Letter
Takeda-backed Ascentage Pharma files for $100M IPO (IPO:NYSEARCA) - Seeking Alpha
Market Capitalization: What It Is, Formula for Calculating It - Investopedia
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares - PR Newswire
Takeda, Ascentage Pharma Sign Option Agreement - Contract Pharma
BIIB Stock Quote Price and Forecast - CNN
Capital Markets - Wilson Sonsini
Morningstar | Empowering Investor Success - Morningstar
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - ADVFN Logo
Ascentage Pharma Group International Adr (AAPG) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):